Theravance Biopharma (TBPH) Long-Term Investments (2014 - 2025)

Theravance Biopharma (TBPH) has 12 years of Long-Term Investments data on file, last reported at $11.1 million in Q4 2025.

• On a quarterly basis, Long-Term Investments rose 385.51% year-over-year to $11.1 million in Q4 2025; TTM through Dec 2025 was $11.1 million, a 385.51% increase from a year earlier, with the FY2025 full-year figure at $11.1 million, up 385.51% from the prior year.
• Long-Term Investments for Q4 2025 stood at $11.1 million, up from $3.0 million in the prior quarter.
• Over the last five years, Long-Term Investments for TBPH reached as high as $148.2 million in Q2 2022 and fell as low as $2.3 million in Q4 2024.
• Historically, Long-Term Investments has averaged $37.5 million across 5 years, with a median of $19.1 million in 2021.
• Across the five-year window, Long-Term Investments jumped 429.7% in 2021 and tumbled 80.05% in 2023, its largest moves.
• Year by year, Long-Term Investments stood at $67.5 million in 2021, then jumped by 119.51% to $148.2 million in 2022, then tumbled by 87.33% to $18.8 million in 2023, then sank by 87.79% to $2.3 million in 2024, then soared by 385.51% to $11.1 million in 2025.
• Per Business Quant data, the three most recent Long-Term Investments figures were $11.1 million in Q4 2025, $3.0 million in Q3 2025, and $2.4 million in Q2 2025.